AstraZeneca PLC

ZEG

Company Profile

  • Business description

    A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

  • Contact

    1 Francis Crick Avenue
    Cambridge Biomedical Campus
    CambridgeCB2 0AA
    GBR

    T: +44 2037495000

    E: [email protected]

    https://www.astrazeneca.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    94,300

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,820.306.40-0.07%
CAC 407,829.2972.96-0.92%
DAX 4024,255.31201.50-0.82%
Dow JONES (US)44,371.51279.13-0.63%
FTSE 1008,941.1234.54-0.38%
HKSE24,139.57111.200.46%
NASDAQ20,585.5345.14-0.22%
Nikkei 22539,569.6876.68-0.19%
NZX 50 Index12,686.6873.52-0.58%
S&P 5006,259.7520.71-0.33%
S&P/ASX 2008,580.109.10-0.11%
SSE Composite Index3,510.180.500.01%

Market Movers